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Abstract
Background: Status epilepticus induces subcellular changes that may lead to neuronal cell death in the
hippocampus. However, the mechanism of seizure-induced neuronal cell death remains unclear. The mitochondrial
uncoupling protein 2 (UCP2) is expressed in selected regions of the brain and is emerged as an endogenous
neuroprotective molecule in many neurological disorders. We evaluated the neuroprotective role of UCP2 against
seizure-induced hippocampal neuronal cell death under experimental status epilepticus.
Methods: In Sprague–Dawley rats, kainic acid (KA) was microinjected unilaterally into the hippocampal CA3
subfield to induce prolonged bilateral seizure activity. Oxidized protein level, translocation of Bcl-2, Bax and
cytochrome c between cytosol and mitochondria, and expression of peroxisome proliferator-activated receptors γ
(PPARγ) and UCP2 were examined in the hippocampal CA3 subfield following KA-induced status epilepticus. The
effects of microinjection bilaterally into CA3 area of a PPARγ agonist, rosiglitazone or a PPARγ antagonist, GW9662
on UCP2 expression, induced superoxide anion (O2•
-) production, oxidized protein level, mitochondrial respiratory
chain enzyme activities, translocation of Bcl-2, Bax and cytochrome c, and DNA fragmentation in bilateral CA3
subfields were examined.
Results: Increased oxidized proteins and mitochondrial or cytosol translocation of Bax or cytochrome c in the
hippocampal CA3 subfield was observed 3–48 h after experimental status epilepticus. Expression of PPARγ and
UCP2 increased 12–48 h after KA-induced status epilepticus. Pretreatment with rosiglitazone increased UCP2
expression, reduced protein oxidation, O2•
- overproduction and dysfunction of mitochondrial Complex I, hindered
the translocation of Bax and cytochrome c, and reduced DNA fragmentation in the CA3 subfield. Pretreatment with
GW9662 produced opposite effects.
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Conclusions: Activation of PPARγ upregulated mitochondrial UCP2 expression, which decreased overproduction of
reactive oxygen species, improved mitochondrial Complex I dysfunction, inhibited mitochondrial translocation of
Bax and prevented cytosolic release of cytochrome c by stabilizing the mitochondrial transmembrane potential,
leading to amelioration of apoptotic neuronal cell death in the hippocampus following status epilepticus.
Keywords: Status epilepticus, Mitochondrial uncoupling protein 2, Peroxisome proliferator-activated receptors γ,
Hippocampal neuronal cell death, Oxidative stress
Background
Epileptic seizure is a major form of acute brain damage that
could lead to a large number of changes at the cellular level,
including oxidative stress, cytokine activation, changes in
plasticity or activation of some late cell death pathways
[1,2]. In particular, prolonged and continuous epileptic
seizures (status epilepticus) results in significant cerebral
damage and increases the risk of subsequent epileptic
episodes, along with a characteristic pattern of preferential
neuronal cell loss in the hippocampus that is accompanied
by long-term behavioral changes and cognitive decline
[3,4]. It follows that prevention of seizure-induced hippo-
campal neuronal damage is also an important goal for treat-
ment of status epilepticus. However, the cellular and
molecular mechanisms via which status epilepticus induces
neuronal cell death in the hippocampus remain to be fully
understood.
Animal [5-8] and human [9] studies suggest that mito-
chondrial dysfunction occur as a consequence of pro-
longed epileptic seizures and may play a pivotal role in
seizure-induced brain damage. Prolonged seizures affect
selectively complex I in the respiratory chain; the induced
oxidative and nitrosative stress precede neuronal cell
death in the hippocampus and cause subsequent epilepto-
genesis [2,10]. Therefore, the mitochondria can be consid-
ered a target for potential neuroprotective strategies in
epilepsy.
The uncoupling proteins (UCPs) have emerged as
important natural antioxidants in the maintenance of re-
active oxygen species (ROS) homeostasis [11]. UCPs be-
long to a superfamily of mitochondrial anion transporters
that uncouple ATP synthesis from oxidative phosphoryl-
ation by causing proton leakage across the mitochondrial
inner membrane, leading to energy dissipation and heat
production [12]. More importantly, the resultant decrease
in proton electrochemical gradient across the inner mito-
chondrial membrane elicited by the UCPs mitigates
mitochondrial ROS production [11,13]. In mammals, five
homologues, UCP1 to UCP5, have so far been cloned [13].
Among them, accumulating evidence suggests that an in-
crease in UCP2 gene expression is related to the decline of
mitochondrial ROS production [14,15]. UCP2 has been
widely studied in the context of obesity, diabetes mellitus
and inflammatory responses [14,16]; an absence of UCP2
potentially promotes ROS accumulation and induces
oxidative damages and inflammatory response. In the cen-
tral nervous system (CNS), UCP2 has been shown to be
upregulated by stress signals such as kainate administra-
tion, injury or ischemia, and overexpression of UCP2 has
been reported to be neuroprotective against oxidative
stress in vivo and in vitro [13,17,18]. However, the exact
mechanism has not been fully established.
We have shown previously that dysfunction of complex I
respiratory chain enzyme and mitochondrial ultrastructural
damage in the hippocampus are associated with prolonged
seizure during experimental temporal lobe status epilepti-
cus [5]. Based on this animal model, our recent studies
[19-22] demonstrated that an excessive production of nitric
oxide (NO) generated by the upregulated NO synthase II
(NOS II), accompanied by an increase in superoxide anion
(O2•
-) production and peroxynitrite formation, followed by a
reduction in mitochondrial complex I activity and release
of cytochrome c from mitochondria to the cytosol, which
triggers the caspase cascades that lead to apoptotic cell
death in the hippocampus. In addition to this detrimental
chain reaction under status epilepticus, it is conceivable
that cellular responses that counteract these detrimental
effects may be activated as an endogenous protective mech-
anism. In this regard, we have demonstrated previously that
rosiglitazone, a peroxisome proliferator-activated receptor γ
(PPARγ) agonist, enhances UCP2 expression after cerebral
ischemia to protect against neuronal cell death in the
hippocampus [23,24]. It follows that as an antioxidant,
UCP2 may be activated during experimental status epilepti-
cus, leading to decreased ROS production, reduced mito-
chondrial dysfunction, impeded apoptotic pathway and
retarded neuronal injury in the hippocampus. Results from
the present study validated this hypothesis.
Methods
All experimental procedures were carried out in compli-
ance with the guidelines for the care and use of experi-
mental animals endorsed by our institutional animal care
committee. All efforts were made to reduce the number of
animals used and to minimize animal suffering during the
experiment.
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Animals
Experiments were carried out in specific pathogen-free
adult male Sprague–Dawley rats (260 to 300 g) that were
obtained from the Experimental Animal Center of the
National Science Council, Taiwan, Republic of China.
They were housed in an animal room under temperature
control (24 to 25°C) and a 12-h light–dark (08:00 to
20:00 h) cycle. Standard laboratory rat chow and tap
water were available ad libitum.
Experimental temporal lobe status epilepticus
An experimental model of temporal lobe status epilepticus
established previously by us [5,19-21] was used. This
model entails microinjection unilaterally of kainic acid
(KA) into the hippocampal CA3 subfield that results in a
progressive buildup of bilateral seizure-like hippocampal
electroencephalographic (hEEG) activity. The head of the
animal was fixed to a stereotaxic headholder (Kopf,
Tujunga, CA, USA) after intraperitoneal (ip) administra-
tion of chloral hydrate (400 mg/kg) to induce anesthesia,
and the rest of the body was placed on a heating pad to
maintain body temperature at 37°C. KA (0.5 nmol; Tocris
Cookson, Bristol, UK) dissolved in 0.1 M PBS, pH 7.4, was
microinjected stereotaxically (3.3 to 3.6 mm posterior to
the bregma, 2.4 to 2.7 mm from the midline, and 3.4 to
3.8 mm below the cortical surface) into the CA3 subfield
of the hippocampus on the left side. The volume of micro-
injection of KA was restricted to 50 nL and was delivered
using a 27-gauge needle connected to a 0.5-μL Hamilton
microsyringe (Reno, NV, USA). This consistently resulted
in progressive and concomitant increase in both root
mean square and mean power frequency values of hEEG
signals recorded from the CA3 subfield on the right side
[5,20,21]. As a routine, these experimental manifestations
of continuous seizure activity were followed by hEEG for
60 minutes, followed by ip administration of diazepam
(30 mg/kg) to terminate seizures [5,20,21]. The wound
was then closed in layers, and sodium penicillin
(10,000 IU; YF Chemical Corporation, Taipei, Taiwan) was
given intramuscularly to prevent postoperative infection.
Animals were returned to the animal room for recovery in
individual cages. Rats that received unilateral microinjec-
tion of 50 nL of PBS and did not exhibit seizure-like hEEG
activities served as our vehicle controls. Animals that
received choral hydrate anesthesia and surgical prepara-
tions without additional experimental manipulations
served as sham-controls.
Pharmacological pretreatments
In experiments that involved pharmacological pretreat-
ments, test agents were microinjected bilaterally and se-
quentially into the CA3 subfield of the hippocampus, at
a volume of 150 nL on each side. Test agents used
included an activator of PPARγ [24,25], rosiglitazone
(Cayman Chemical, Ann Arbor, MI, USA) and a PPARγ
antagonist [25,26], GW9662 (Cayman Chemical). The
doses of test agents used were 6 nmol for rosiglitazone,
and 500 ng for GW9662 [24,26]. Microinjection of 3%
dimethyl sulfoxide (DMSO) solvent served as the vehicle
and volume control. To avoid the confounding effects of
drug interaction, each animal received only one single
pharmacological pretreatment, followed 30 minutes later
by microinjection of KA (0.5 nmol) or PBS into the left
hippocampal CA3 subfield.
Collection of tissue samples from the hippocampus
At predetermined time intervals (3, 6, 12, 24 or 48 h; or
7 days) after microinjection of KA or PBS into the
hippocampus, rats were again anesthetized by ip admin-
istration of chloral hydrate (400 mg/kg,) and were per-
fused intracardially with 50 mL of warm (37°C) saline
that contained heparin (100 U/mL). As we reported pre-
viously [5,19-21], the brain was rapidly removed under
visual inspection and placed on a piece of gauze mois-
tened with ice-cold 0.9% saline. We routinely collected
tissues from the ipsilateral (injection side for KA) and
the contralateral (recording side for hEEG) hippocampal
CA3 subfield [5,19-21]. Hippocampal samples were
stored at −80°C until biochemical analysis. In experi-
ments involving immunofluorescence staining, brains
were post-fixed in 4% paraformaldehyde for 48 h at 4°C
followed by cryoprotection with 30% sucrose solution.
The concentration of total proteins extracted from tissue
samples was determined by the bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL, USA). In
some experiments, proteins from the nuclear or cyto-
solic fraction of the hippocampal samples were extracted
by a commercial kit (Active Motif, Carlsbad, CA, USA).
Measurement of protein oxidation
Oxidized protein was determined using a protein oxida-
tion detection kit (OxyBlot, Chemicon, Temecula, CA,
USA). This kit provides reagents for sensitive immuno-
detection of the carbonyl group, which is a hallmark of
the oxidation status of proteins [27,28]. Total proteins
extracted from the hippocampal CA3 subfield were
reacted with 2,4-dinitrophenylhydrazine and derivatized
to 2,4-dinitrophenylhydrazone (DNP-hydrazone) [29].
The DNP-derivatized protein samples were separated on
a 15% SDS-polyacrylamide gel followed by western blot.
The blot was incubated with a rabbit anti-DNP antibody,
followed by incubation with a horseradish peroxidase-
conjugated goat anti-rabbit IgG according to manufac-
turers’ instructions.
Western blot analysis
Western blot analysis for UCP2, PPARγ, Bcl-2, Bax,
cytochrome c or β-actin was carried out on proteins
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extracted from nuclear fractions or from mitochondrial
or cytosolic fractions of hippocampal samples. The pur-
ity of the mitochondrial fraction was verified by the se-
lective expression of the mitochondrial inner membrane-
specific protein, cytochrome c oxidase subunit IV (COX
IV). Protein concentration was determined by the BCA
Protein Assay (Pierce). The primary antisera used included
rabbit polyclonal antiserum against Bax and COX IV (Cell
Signaling, Danvers, MA, USA), goat polyclonal antiserum
against UCP2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), mouse monoclonal antiserum against Bcl-2,
cytochrome c and PPARγ (Santa Cruz Biotechnology) or
β-actin (Chemicon, Temecula, CA, USA). β-actin was
used for internal control of total protein or proteins in the
cytosolic fraction, and COX IV for proteins in the mito-
chondrial fraction. . The secondary antisera used included
horseradish peroxidase-conjugated sheep anti-mouse IgG
(Amersham Biosciences, Little Chalfont, UK) for Bcl-2,
cytochrome c, PPARγ and β-actin; donkey anti-goat IgG
(Chemicon) for UCP2, or donkey anti-rabbit IgG (Amer-
sham Biosciences) for Bax, and COX IV. Specific
antibody-antigen complex was detected by an enhanced
chemiluminescence western blot detection system (NEN,
Boston, MA, USA). The amount of protein was quantified
by ImageMaster software (Amersham Pharmacia Biotech,
Piscataway, NJ, USA), and was expressed as the ratio rela-
tive to β-actin protein (for analysis of total protein or pro-
teins in the cytosolic fraction) or COX IV (for analysis of
proteins in the mitochondrial fraction).
RNA isolation and reverse transcription real-time
polymerase chain reaction
For quantitative analysis of Ucp2 mRNA expression in the
hippocampal CA3, at 3, 6, 12 h or 24 h after microinjection
of KA or PBS into the hippocampus, the brain was rapidly
removed and total RNA from the hippocampal CA3 was
isolated with TRIzol reagent (Invitrogen) according to the
manufacturer’s protocol. All RNA isolated was quantified
by spectrophotometry and the optical density 260/280 nm
ratio was determined. RT reaction was performed using a
SuperScript Preamplification System (Invitrogen) for the
first-strand cDNA synthesis [25,30]. Real-time PCR for
amplification of cDNA was performed using a LightCycler
(Roche Diagnostics, Mannheim, Germany). PCR for each
sample was carried out in duplicate for all cDNAs and for the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) con-
trol [25,30]. The PCR mixture (total volume 20 μl), which
was prepared with nuclease-free water, contained 2 μL of
LightCycler FastStart DNA Master SYBR Green 1 (Roche
Diagnostics), 3 mM MgCl2, and 5 μM each primer, together
with 5 μL of purified DNA or negative control. The primer
pairs for amplifi-cation of Ucp2 cDNA (GenBank: U69135)
were 5′-TCCCCTGTTGATGTGGTCAA-3′ for the forward
primer, and 5′-CAGTGACCTGCGCTGTGGTA-3′ for the
reverse [25]. Primer pairs for GAPDH cDNA (GenBank:
NM017008) were 5′-GCCAAAAGGGTCATCATCTC-3′ for
the forward primer, and 5′-GGCCATCCACAGTCTTCT-3′
for the reverse [25]. The amplification protocol for cDNA
was a 10-minute denaturation step at 95°C for polymerase
activation; a so-called touchdown PCR step of 10 cycles con-
sisting of 10 s at 95°C, 10s at 65°C, and 30s at 72°C; followed
by 40 cycles consisting of 10 s at 95°C, 10 s at 55°C, and 30s
at 72°C. After slow heating (0.1°C per second) of the ampli-
fied product from 65 to 95°C to generate a melting
temperature curve, which serves as a specificity control, the
PCR samples were cooled to 40°C. The PCR products were
subsequently subjected to agarose gel electrophoresis for fur-
ther confirmation of amplification specificity. Fluorescence
signals from the amplified products were quantitatively
assessed using the LightCycler software program (version
3.5). Second derivative maximum mode was chosen with
baseline adjustment set in the arithmetic mode. The relative
change in Ucp2 mRNA expression was determined by the
fold-change analysis [25], in which:
Fold change = 2−(ΔΔCt)
where:
ΔΔCt ¼ CtUCP2−CtGAPDHð Þpharmacological treatment
− CtUCP2−CtGAPDHð ÞcontrolÞ
Note that Ct value is the cycle number at which the
fluorescence signal crosses the threshold.
Double immunofluorescence staining and laser confocal
microscopy
Free-floating sections of the hippocampus (35 μm)
were processed for double immunofluorescence
staining by procedures we reported previously [19-
21]. Double immunofluorescence staining was carried
out using a rabbit polyclonal antiserum against
UCP2 (Bioss, Woburn, MA, USA) or against a mar-
ker for astrocytes, glial fibrillary acidic protein
(GFAP; Abcam, Cambridge, UK); or rabbit polyclonal
antiserum against a mitochondrial membrane pro-
tein, COX IV (Cell Signaling). The secondary anti-
sera included a goat anti-rabbit IgG conjugated with
AlexaFluor 488 and a goat anti-mouse IgG conju-
gated with Alexa Fluor 568 or a goat anti-rabbit IgG
conjugated with AlexaFluor 546 (Molecular Probes,
Eugene, OR, USA). Hippocampal CA3b area was
viewed under a Fluorview FV10i laser scanning con-
focal microscope (Olympus, Tokyo, Japan), and
immunoreactivity for NeuN, COX IV or GFAP
exhibited red fluorescence and UCP2 manifested
green fluorescence. The exhibition of yellow
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fluorescence on merged images indicated the pres-
ence of UCP2 immunoreactivity in neurons, mito-
chondria or astrocytes.
Measurement of superoxide anion production
Measurement of O2•
- production was determined by
lucigenin-enhanced chemiluminescence [21,31]. Fresh
samples from the hippocampal CA3 subfield were
homogenized in 20 mM sodium phosphate buffer,
pH 7.4, containing 0.01 mM EDTA by a glass-to-
glass homogenizer. The homogenate was subject to
centrifugation at 1000 g for 10 minutes at 4 °C to re-
move nuclei and unbroken cell debris. The pellet
was discarded and the supernatant was obtained
immediately for O2•
- measurement. Background
chemiluminescence in buffer (2 mL) containing luci-
genin (5 μM) was measured for 5 minutes. An
aliquot of 100 μl of supernatant was then added, and
the chemiluminescence measured for 30 minutes
at room temperature with a Sirius luminometer
(Berthold, Germany) [21]. O2•
-production was calcu-
lated and expressed as mean light units per minute
per mg protein. Specificity for O2•
- was determined
by adding superoxide dismutase (SOD) (350 U/mL)
into the incubation medium.
Assays for activity of mitochondrial respiratory enzymes
Isolation of rat mitochondria from the hippocampal sam-
ples was carried out according to our previous report [5,21]
and modification [32]. Hippocampal tissues were sus-
pended in wash buffer and homogenized in an ice-cold
mitochondrial isolation buffer kit (MS850, MitoSciences,
Eugene, OR, USA) using a loose-fit 2 mL glass
homogenizer (Kontes, Vineland, NJ, USA). The homogen-
ate was centrifuged at 1000 g for 10 minutes at 4°C, and the
supernatant obtained was further centrifuged at 12000 g for
15 minutes. The pellet was resuspended in isolation buffer
and protease inhibitor was added, and then centrifuged at
12000 g for 15 minutes. The final mitochondrial pellet was
suspended in a minimal amount of isolation buffer and pro-
tease inhibitor and stored at −80°C until measurement of
mitochondrial respiratory enzyme activity, which was
undertaken within 3 days. Total protein in the mitochon-
drial suspension was determined by the BCA Protein Assay
(Pierce, Rockford, IL, USA), using bovine serum albumin as
a standard.
The activity of complex I (nicotinamide adenine di-
nucleotide (NADH) ubiquinone oxidoreductase) and com-
plex IV (cytochrome c oxidase) of mitochondrial
respiratory enzymes were analyzed by enzyme activity
immunocapture assays [32,33]. A 96-well plate coated with
monoclonal antibodies against the oxidative phosphoryl-
ation complex I (MS141, MitoSciences) and IV (MS444,
MitoSciences) were used according to manufacturers’
instructions. Complex I activity was measured by adding
an assay solution and the oxidation of NADH was moni-
tored by measuring its decrease in absorbance at 450 nm
in kinetic mode at 30°C for 2 h. Complex IV activity was
measured by adding an assay solution and the oxidation of
reduced cytochrome c was monitored by measuring its de-
crease in absorbance at 550 nm in kinetic mode at room
temperature for 30 minutes. Assays for mitochondrial re-
spiratory enzyme activity were performed using a Multis-
kan Spectrum reader (Thermo Scientific, Miami, USA). At
least duplicate determination was carried out on each tis-
sue sample.
Qualitative and quantitative analysis of DNA
fragmentation
Tissue samples from the hippocampal CA3 subfield
were subject to qualitative and quantitative analysis of
DNA fragmentation. After extraction of total DNA
from hippocampal tissues, nucleosomal DNA ladders
were amplified by a PCR kit for DNA ladder assay
(Maxim Biotech, San Francisco, CA, USA) to enhance
the detection sensitivity, and were separated by elec-
trophoresis on 1% agarose gel [19-21]. To quantify
apoptosis-related DNA fragmentation, a cell death
ELISA (Roche Molecular Biochemicals, Mannheim,
Germany) that detects apoptotic but not necrotic cell
death [34] was used to assay the level of histone-
associated DNA fragments in the cytoplasm [35]. Pro-
teins from the cytosolic fraction of hippocampal sam-
ples were used as the antigen source, together with
primary anti-histone antibody and secondary anti-
DNA antibody coupled to peroxidase. The amount of
nucleosomes in the cytoplasm was quantitatively
determined using 2,2′-azino-di-[3-ethylbenzthiazoline]
sulfonate as the substrate. Absorbance was measured
at 405 nm and referenced at 490 nm using a microti-
ter plate reader (Anthros Labtec).
Statistical analysis
One-way analysis of variance (ANOVA) was used, as ap-
propriate, to assess group means, followed by the Scheffé
multiple-range test for post hoc assessment of individual
means. All values are expressed as mean ± standard error
of the mean (SEM). A P-value< 0.05 was taken to indi-
cate statistical significance.
Results
Strategies for biochemical analyses and pharmacological
treatments
As in our previous studies [5,19-22], we routinely carried
out biochemical analysis separately on tissues collected
from the ipsilateral (injection side for KA) and the
contralateral (recording side for hEEG) hippocampal
CA3 subfield. This allowed us to ascertain that results
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from those analyses were consequential directly to ex-
perimental temporal lobe status epilepticus and not in-
directly to KA excitotoxicity. Since seizure activity was
activated bilaterally, test agents were also routinely
microinjected into the bilateral hippocampal CA3 sub-
field to confirm that parallel results were obtained from
CA3 areas on both sides.
Temporal changes in protein oxidation in the
hippocampal CA3 subfield following experimental
temporal lobe status epilepticus
We reported recently [21] that a significant surge in
O2•
- production took place as early as 3 h after the
induction of experimental temporal lobe status epi-
lepticus, which gradually declined over 24 h. Our
first series of experiments therefore, established that
oxidative stress damages occurred in hippocampal
CA3 neural cells following experimental lobe status
epilepticus. We observed a significantly heightened
content of oxidized proteins in the ipsilateral hippo-
campal CA3 subfield as early as 3 h, followed by a
progressive reduction over 24 h after unilateral
microinjection of KA (0.5 nmol) into the left CA3
area (Figure 1). We also observed a significant in-
crease in oxidized proteins in the contralateral CA3
subfield over the same time intervals after local ap-
plication of KA into the left hippocampal CA3 sub-
field. Importantly, the temporal changes of protein
oxidations in the bilateral hippocampal CA3 subfield
paralleled the time course of O2•
- production after ex-
perimental status epilepticus [21].
Temporal course of Bax and cytochrome c translocation
in the hippocampal CA3 subfield following experimental
temporal lobe status epilepticus
Our second series of experiments investigated whether
the Bcl-2, Bax and cytochrome c signaling cascades are
associated with excessive ROS production in the hippo-
campal CA3 subfield following experimental temporal
lobe status epilepticus. Western blot analysis revealed that
Bcl-2 was not discernibly altered in either the mitochon-
drial or cytosolic fraction of samples obtained from the
hippocampal CA3 subfield. However, there was a signifi-
cant decrease of Bax level and increase of cytochrome c
level in the cytosolic fraction (Figure 2A) of samples from
the bilateral hippocampal CA3 subfield after unilateral
microinjection of KA (0.5 nmol) into the left CA3 region,
accompanied by a corresponding increase of Bax level and
decrease of cytochrome c level in the mitochondrial
fraction (Figure 2B). Of note is that this induced
mitochondria-bound translocation of Bax from the cytosol
and cytosol-bound translocation of cytochrome c from the
mitochondria followed a time frame that started from 3 h
in the ipsilateral and 6 h in the contralateral CA3 area,
and was sustained 48 h after the induction of experimental
temporal lobe status epilepticus.
Figure 1 Representative gels (inset) or temporal changes of protein oxidation detected in samples collected from the CA3 subfield of
the hippocampus at 3, 6, 12, 24 and 48 h after microinjection of 0.5 nmol kainic acid (KA) or PBS into the left hippocampal CA3
subfield. Total proteins were extracted from the hippocampal CA3 subfield at the indicted times or from sham-operated controls followed by
immunoblot analysis for the extent of protein oxidation. Values in the lower panel are fold changes with reference to sham-control (S) and are
mean± standard error of the mean (SEM) of four animals per experimental group. *P< 0.05 versus sham-control group in the Scheffé
multiple-range test.
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Figure 2 (See legend on next page.)
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Temporal changes of PPARγ and UCP2 expression in the
hippocampal CA3 subfield following experimental
temporal lobe status epilepticus
Our third series of experiments examined whether PPARγ
and UCP2 in the hippocampal CA3 subfield exhibit
changes in expression level following experimental tem-
poral lobe status epilepticus. After unilateral microinjec-
tion of KA into the left CA3 region, western blot analysis
revealed a slight decrease of PPARγ 6 h after ipsilateral
KA treatment, followed by a significant increase of expres-
sion from 12 to 48 h in the bilateral hippocampal CA3
subfields (Figure 3A). More intriguingly, real-time PCR
analysis (Figure 3B) revealed that Ucp2 mRNA underwent
a significant increase in the bilateral hippocampal CA3
area that peaked at 6 h after the elicitation of sustained
hippocampal seizure discharges. Also, western blot ana-
lysis showed a significant increase of UCP2 protein ex-
pression from 12 to 48 h in both hippocampal CA3
subfields (Figure 3C) that paralleled the augmented ex-
pression of PPARγ.
Effects of rosiglitazone and GW9662 on UCP2 expression
in hippocampal CA3 neurons following experimental
temporal lobe status epilepticus
Our fourth series of experiments further explored a causal
role for PPARγ and UCP2 in experimental temporal lobe
status epilepticus. Bilateral microinjection of the PPARγ
agonist, rosiglitazone (6 nmol) into the hippocampal CA3
region significantly increased the expression of UCP2 in
the mitochondrial fraction (Figure 4) from the CA3 sub-
field 24 h after the elicitation of sustained hippocampal
seizure discharges. On the other hand, bilateral micro-
injection of the PPARγ antagonist, GW9662 (500 ng)
reduced the elicited UCP2 expression (Figure 4). Similar
observations were obtained from double immunofluores-
cence staining coupled with laser scanning confocal mi-
croscopy. Compared to sham-control (Figure 5A), there
was an increase in UCP2 immunoreactivity in neurons
from the hippocampal CA3 subfield on the right side
(Figure 5B) 24 h after KA-induced status epilepticus.
Moreover, whereas pretreatment with rosiglitazone
(6 nmol) increased (Figure 5C), GW9662 (500 ng) pre-
treatment decreased (Figure 5D) UCP2 immunoreactivity
in the hippocampal CA3 neurons.
We also verified the localization of UCP2 immunoreactiv-
ity in mitochondria by co-immunofluorescence staining
with the mitochondrial membrane protein, COX IV
(Figure 5E-H) of hippocampal CA3 neurons on the right
side (Figure 5F), 24 h after KA-induced status epilepticus
compared with sham-control (Figure 5E). Additionally,
pretreatment with rosiglitazone (6 nmol) increased
(Figure 5G), and GW9662 (500 ng) pretreatment
decreased (Figure 5H) UCP2 immunoreactivity in the
mitochondria of hippocampal CA3 neurons. However, the
immunoreactivity for UCP2 was not significantly changed
in hippocampal cells that were immunoreactive to the
astrocyte marker GFAP 24 h following experimental status
epilepticus (Figure 5I-L).
Effects of rosiglitazone and GW9662 on superoxide
production and oxidized protein expression in the
hippocampal CA3 subfield following experimental
temporal lobe status epilepticus
To strengthen a pivotal role of the PPARγ/UCP2 signal-
ing pathway in oxidative stress damage in the hippocam-
pus following experimental status epilepticus, we
observed that bilateral microinjection of rosiglitazone
into the hippocampal CA3 region, at a dose (6 nmol)
that enhanced UCP2 expression, also decreased the
levels of O2•
- ((Figure 6A) or oxidized protein (Figure 6B)
in the CA3 subfield 24 h after KA-induced experimental
status epilepticus. On the other hand, pretreatment with
GW9662 (500 ng) increased the levels of O2•
- (Figure 6A)
or oxidized protein (Figure 6B).
Effects of rosiglitazone and GW9662 on the activity of
mitochondrial respiratory enzymes in the hippocampal
CA3 subfield following experimental temporal lobe status
epilepticus
Our laboratory reported previously [5,21] that depression
of mitochondrial complex I and preservation of complex
IV enzyme activity in the hippocampus takes place in our
experimental model of temporal lobe status epilepticus.
Our next series of experiments examined whether the
induced mitochondrial dysfunction is causally related to
upregulation of UCP2. We found that the significantly
reduced complex I respiratory enzyme activity in the bilat-
eral hippocampal CA3 subfield 3 and 24 after local appli-
cation of KA into the left CA3 subfield was significantly
(See figure on previous page.)
Figure 2 Representative gels (inset) or temporal changes in Bcl-2, Bax or cytochrome c relative to β-actin protein detected in the
cytosolic fraction or relative to cytochrome c oxidase subunit IV (COX-IV) in the mitochondrial fraction of samples collected from the
CA3 subfield of the hippocampus after microinjection of kainic acid (KA) or PBS. (A) Cytosolic fraction and (B) mitochondrial fraction of
samples collected 3, 6, 12, 24 and 48 h after microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield. β-actin or COX-IV was
used as the internal loading control for the cytosolic or mitochondrial fraction. Values are mean± standard error of the mean (SEM) of the ratio of
Bcl-2, Bax or cytochrome c to the loading controls, and are quadruplicate analyses from six animals per experimental group. *P< 0.05 versus
sham-control (S) group in the Scheffé multiple-range test.
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Figure 3 Temporal changes in peroxisome proliferator-activated receptor γ (PPARγ) protein relative to β-actin protein and UCP2
protein relative to cytochrome c oxidase subunit IV (COX-IV), and real-time PCR analysis showing fold changes in uncoupling protein 2
(Ucp2) mRNA expression relative to glyceraldehyde-3-phosphate dehydrogenase after microinjection of kainic acid or PBS into the left
hippocampal CA3 subfield. (A) Changes in PPARγ protein relative to β-actin protein. (B) Fold changes in Ucp2 mRNA expression relative to
glyceraldehyde-3-phosphate dehydrogenase. (C) Changes in UCP2 protein relative to COX-IV. Changes were detected in samples collected from
the CA3 subfield of the hippocampus at 3, 6, 12, 24 or 48 h after microinjection of 0.5 nmol kainic acid or PBS into the left hippocampal CA3
subfield. Values are mean± standard error of the mean (SEM) of quadruplicate analyses from six animals per experimental group. *P< 0.05 versus
sham-control group (S) in the Scheffé multiple-range test.
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blunted by pretreatment with rosiglitazone (6 nmol)
(Figure 7A). However, the induced dysfunction of complex
I was aggravated by pretreatment with GW9662 (500 ng)
(Figure 7A). On the other hand, there was a lack of dis-
cernible changes in complex IV activities 3 and 24 h after
experimental status epilepticus in animals pretreated with
rosiglitazone or GW9662 (Figure 7B).
Effects of rosiglitazone and GW9662 on apoptotic cell
death in the hippocampal CA3 subfield following
experimental temporal lobe status epilepticus
We have shown previously that an excessive oxidative and
nitrosative stress followed by the release of cytochrome c
to the cytosol that triggers the caspase cascades, leads to
apoptotic cell death in the hippocampus during experi-
mental status epilepticus [20,21]. Our final series of
experiments explored whether the upregulated PPARγ/
UCP2 signaling pathway plays a significant role in ameli-
orating this process. We found that whereas pretreatment
with rosiglitazone (6 nmol) significantly reduced, the ex-
tent of Bax translocation from cytosol to mitochondria
and cytochrome c translocation from mitochondria to
cytosol in the CA3 areas 24 h after experimental temporal
lobe status epilepticus, GW9662 (500 ng) significantly
augmented it (Figure 8). Comparable results were
obtained from qualitative (Figure 9A) and quantitative
Figure 5 Laser scanning confocal microscopic images of the right CA3b subregion of hippocampus showing cells that were
immunoreactive to a neuronal marker, a mitochondrial protein marker, or a marker for astrocytes, and additionally stained for
uncoupling protein (UCP)-2. Scanning was performed 24 h after microinjection of 0.5 nmol kainic acid (KA) or PBS into the left hippocampal
CA3 subfield in animals that received pretreatment with application into the bilateral CA3 subfield of 3% dimethyl sulfoxide (DMSO), 6 nmol
rosiglitazone (RGZ) or 500 ng GW9662. (A-D) Neuronal marker, NeuN (red fluorescence). (E-H) Mitochondrial protein marker, cytochrome c
oxidase subunit IV (COX IV) (red fluorescence). (I-L) Marker for astrocytes, glial fibrillary acidic protein (GFAP) (red fluorescence). Cells were
additionally stained for UCP2 (green fluorescence). Note that double-labeled neurons, mitochondria or astrocytes displayed yellow fluorescence.
These results are typical of three animals from each experimental group. Scale bar, 5 μm in 5A-H; 2 μm in 5I-L.
Figure 4 Representative gels (inset) or changes in uncoupling
protein (UCP)-2 relative to cytochrome c oxidase subunit IV
(COX-IV), detected in the mitochondrial fraction of samples
collected from the CA3 subfield of the hippocampus 24 h after
microinjection of 0.5 nmol kainic acid or PBS into the left
hippocampal CA3 subfield after pretreatment with 3%
dimethyl sulfoxide (DMSO), rosiglitazone (RGZ, 6 nmol) or
500 ng GW9662 applied to the bilateral CA3 subfield. Values are
mean± standard error of the mean (SEM) of quadruplicate analyses
from six animals per experimental group. *P< 0.05 versus sham-
control group, +P< 0.05 versus sham-control, DMSO+ KA or
GW9662+ KA group, and #P< 0.05 versus sham-control, DMSO+ KA
or RGZ+ KA group in the Scheffé multiple-range test.
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(Figure 9B) analysis of DNA fragmentation as another
index for apoptosis, 7 days after the induction of status
epilepticus.
Discussion
Based on a clinically relevant animal model, the present
study provided novel evidence to support an antioxidant
role for UCP2 in temporal lobe status epilepticus.
Specifically, our results revealed that upregulation of
UCP2 expression induced by experimental status epilep-
tics decreased oxidative stress, reduced mitochondrial
dysfunction, blunted mitochondrial intrinsic apoptotic
cell death pathway and protected against neuronal cell
death in the hippocampal CA3 subfield.
PPARs are known to modulate the inflammatory and
oxidative response [36]. The beneficial effects of PPARs
Figure 6 Representative changes in superoxide anion (O2•
-) production and protein oxidation in the bilateral CA3 subfield of the
hippocampus 24 h after microinjection of kainic acid (KA) (0.5 nmol) or PBS into the left hippocampal CA3 subfield in animals that
received pretreatment with application into the bilateral CA3 subfield of 3% dimethyl sulfoxide (DMSO), 6 nmol rosiglitazone (RGZ) or
500 ng GW9662. (A) Changes in O2•
- production. (B) Changes in protein oxidation. Values are mean± standard error of the mean (SEM) of
quadruplicate analyses from four animals per experimental group. *P< 0.05 versus sham-control group, +P< 0.05 versus sham-control,
DMSO+ KA or GW9662+ KA group, and #P< 0.05 versus sham-control, DMSO+ KA or RGZ+ KA group in the Scheffé multiple-range test.
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in inflammatory diseases are exerted through regulation
of cytokine production and adhesion molecule expres-
sion by interfering with transcription factors, including
nuclear factor-κB (NF-κB), activator protein-1 (AP-1),
signal transducers and activators of transcription
(STATs) [36-38]. Treatments with PPARγ agonists in-
crease the expression of UCP2 in both animal and cell
studies [25,39,40], suggesting that UCP2 may be regu-
lated by PPARγ activity. We have demonstrated previ-
ously [23,24] that the PPARγ agonist, rosiglitazone
enhances UCP2 expression in the hippocampal neurons,
leading to protection against oxidative stress and neur-
onal cell death associated with cerebral ischemia. We
also showed previously [25] that gene knockdown of
UCP2 by antisense oligonucleotide or pharmacological
pretreatment with PPARγ agonist and antagonist also
pointed to an antioxidative role for UCP2 in the brain
stem against neurogenic hypertension. Moreover, in
mice overexpressing human UCP-2 gene, brain damage
was diminished after experimental stroke and traumatic
Figure 7 Enzyme assay for the activity of complex I or complex IV in mitochondria isolated from the CA3 subfield of the hippocampus
3 h and 24 h after microinjection of kainic acid (KA) (0.5 nmol) or PBS into the left hippocampal CA3 subfield, in animals that received
pretreatment with application into the bilateral CA3 subfield of 3% dimethyl sulfoxide (DMSO), 6 nmol rosiglitazone (RGZ) or 500 ng
GW9662. (A) Complex I. (B) Complex IV. Values are fold changes with reference to sham-control and are mean± standard error of the mean
(SEM) of four animals per experimental group. *P< 0.05 versus sham-control group, +P< 0.05 versus sham-control, DMSO+ KA or GW9662 + KA
group, and #P< 0.05 versus sham-control, DMSO+ KA or RGZ+ KA group in the Scheffé multiple-range test.
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brain injury, and neurological recovery was enhanced
[18]. In rat cultured cortical neurons, overexpression of
UCP-2 gene reduced cell death and inhibited caspase-3
activation induced by oxygen and glucose deprivation
[18]. It is intriguing that results from the present study
also showed that pretreatment with rosiglitazone
increased mitochondrial UCP2 expression, reduced the
extent of protein oxidation, O2•
- overproduction and dys-
function of mitochondrial respiratory enzyme complex I,
hindered the translocation of Bax or cytochrome c
between cytosol and mitochondria and reduced neuronal
damage in the hippocampal CA3 subfield elicited by ex-
perimental status epilepticus. In contrast, treatment with
the PPARγ antagonist, GW9662 exerted opposite effects.
Thus, the present study provided a novel demonstration
of an antioxidant role for the PPARγ/UCP2 signaling
pathway against oxidative stress and mitochondrial dys-
functions that reduced neuronal cell injury in the hippo-
campal CA3 subfield after the experimental model of
temporal lobe status epilepticus.
Figure 8 Representative gels (inset) or temporal changes in Bcl-2, Bax or cytochrome c relative to β-actin protein detected in the
cytosolic or relative to cytochrome c oxidase subunit IV (COX-IV) in the mitochondrial fraction of samples collected from the CA3
subfield of the hippocampus 24 h after microinjection of kainic acid (KA) (0.5 nmol) or PBS into the left hippocampal CA3 subfield, in
animals that received pretreatment with application into the bilateral CA3 subfield of 3% dimethyl sulfoxide (DMSO), 6 nmol
rosiglitazone (RGZ) or 500 ng GW9662. (A) Cytosolic fraction and (B) mitochondrial fraction of samples. Values are mean± standard error of
the mean (SEM) of quadruplicate analyses from six animals per experimental group. *P< 0.05 versus sham-control group, +P< 0.05 versus sham-
control, DMSO+ KA or GW9662+ KA group, and #P< 0.05 versus sham-control, DMSO+ KA or RGZ+ KA group in the Scheffé multiple-range test.
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Neuroprotection following prolonged seizures, such as
status epilepticus should encompass not only the pre-
vention of neuronal cell death, but also preservation of
neuronal and network function. Less well studied are the
protective mechanisms elicited by seizure activity espe-
cially under status epilepticus. Except for the detrimental
chain reaction under status epilepticus, acute response
protein to counteract these detrimental effects may be
elicited as an endogenous protective mechanism. En-
dogenous neuronal survival mechanisms following pro-
longed seizure insult are those that have been
evolutionarily conserved and may trigger a number of
signaling pathways to exert the protective effect and
therefore be strong candidates to imply as therapeutic
strategies [41]. In animal studies with status epilepticus,
several endogenous protective mechanisms to lessen
neuronal damage were proposed, including activation
ERK1/2, epileptic tolerance, vascular endothelial growth
factor, activation of adenosine A1 receptors, erythropoi-
etin receptor [41-45]. Based on real-time PCR and west-
ern blot analyses, we demonstrated a significant increase
in UCP2 mRNA in the hippocampal CA3 subfield after
KA-elicited status epilepticus, followed by augmented
UCP2 protein levels. In addition, immunofluorescence
staining demonstrated that the activated UCP2 was
mainly in the mitochondria of hippocampal CA3 neu-
rons. Thus, our results suggested that mitochondrial
UCP2 may play an endogenous neuroprotective role
Figure 9 Analysis of DNA fragmentation detected in samples collected from the CA3 subfield of the hippocampus 7 days after
microinjection of kainic acid (KA) (0.5 nmol) or PBS into the left hippocampal CA3 subfield in animals that received pretreatment with
application into the bilateral CA3 subfield of 3% dimethyl sulfoxide (DMSO), 6 nmol rosiglitazone (RGZ) or 500 ng GW9662. (A)
Qualitative analysis. (B) Quantitative analysis. Values in panel B are fold changes with reference to sham-control and are mean± standard error of
the mean (SEM) of four animals per experimental group. *P< 0.05 versus sham-control group, +P< 0.05 versus sham-control, DMSO+ KA or
GW9662+ KA group, and #P< 0.05 versus sham-control, DMSO+ KA or RGZ+ KA group in the Scheffé multiple-range test.
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against hippocampal neuronal cell damage under the
stress of prolonged epileptic seizures.
Several antioxidant systems are present in the cell to
counteract oxidative stress and to restore redox balance,
and may be considered endogenous protective mechanisms
under pathological conditions. In addition to the documen-
ted ROS-detoxifying enzymes and low molecular weight
antioxidants, whether mitochondrial UCP functions as a
natural antioxidant defense mechanism against oxidative
stress is still debatable. Mitochondrial UCPs control the
leakage of protons across the inner mitochondrial mem-
brane and have emerged as an important modulator for
oxidative stress [17,46]. As UCP2 are most prevalent in the
nervous system, and a majority of the neurodegenerative
disorders engages free radical production [13,17,46], it is
reasonable to propose that UCP2 induction will be involved
in these neurological disorders, including status epilepticus.
Although the physiological role of UCP2 is still not clear,
emerging evidence suggests that UCP2 may be related to
the regulation of mitochondrial membrane potential, regu-
lation of ROS production, preservation of calcium homeo-
stasis, modulation of neuronal activity, and inhibition of
cellular damage and inflammation [17,46,47]. Several recent
studies stressed the role of protective effects of UCP2
against the neuronal cell damage after cerebral ischemia
and brain trauma [18,24,46-49]; limited studies explored
the role of UCP2 in epileptic seizures. In transgenic mice
that express UCP2 constitutively in the hippocampus, there
is an attenuation of seizure-induced neuronal death and an
increase in mitochondrial number and ATP levels, along-
side a parallel decrease in free radical-induced damage [50].
Modulation of UCP2 expression and function by dietary fat
protects neonatal rats against seizure-induced brain dam-
age associated with oxidative stress and mitochondrial dys-
function [51]. In the present study, we found that
mitochondrial UCP2 was significantly upregulated in the
hippocampal CA3 region 12 to 48 h after the induction of
experimental status epilepticus, at a time-point that lagged
behind the increase in protein carbonylation and O2•
- These
results indicate that the endogenous activation of mito-
chondrial UCP2 in hippocampal CA3 neurons under pro-
longed epileptic seizures may be a consequence of the
increase in ROS production.
Mitochondrial dysfunction has been implicated as an im-
portant factor in the pathogenesis of seizure-induced neur-
onal cell death [2,10,52]. As the cellular powerhouse, the
primary function of mitochondria is the production of cel-
lular energy in the form of ATP by way of oxidative phos-
phorylation through the mitochondrial respiratory chain
[53]. However, mitochondrial metabolism is also respon-
sible for a majority of ROS production in cells and complex
I of the mitochondrial electron transport chain is noticeably
more susceptible to both oxidative and nitrosative stress
than other respiratory chain complexes [54]. Dysfunction of
complex I may lead to incomplete mitochondrial electron
transport and reduced ATP production. We reported previ-
ously [5,19-21] that activation of NF-κB in hippocampal
CA3 neurons upregulates NOS II gene expression, accom-
panied by an increase in O2•
- production and peroxynitrite
formation, followed by reduction in mitochondrial complex
I activity, leading to apoptotic neuronal cell death in the
hippocampus via the intrinsic mitochondrial apoptotic
pathway. Therefore, the dysfunction of complex I may be
an important biochemical hallmark of seizure-induced
neuronal cell death in the hippocampus and may play a
crucial role in the mechanism of epileptogenesis [2,10]. It
follows that our demonstration of an increase or decrease
in mitochondrial UCP2 expression induced by rosiglitazone
or GW9662 underlying the attenuation or exacerbation of
seizure-induced mitochondrial complex I dysfunction, sug-
gests that another cellular role for UCP2 induced by experi-
mental status epilepticus is amelioration of bioenergetics
inefficiency in the hippocampus. Thus, UCP-2 may be an
inducible protein that provides a neuroprotective effect by
activating cellular redox signaling as well as by inducing
mild mitochondrial uncoupling [18].
One of the decisive steps of the apoptotic cascade is
permeabilization of the outer mitochondrial membrane
[55], which leads to the release of cytochrome c from
the intermediate space, followed by the activation of
caspase-dependent apoptotic signaling. It is generally
contended that the anti-apoptotic members of the Bcl-2
family work to prevent cytochrome c release by stabiliz-
ing the mitochondrial membrane barrier function and
the pro-apoptotic members tend to induce cytochrome c
release by permeabilizing the mitochondrial membrane
[55,56]. Translocation of Bax from the cytosol to mito-
chondria is induced during apoptosis, and this process is
inhibited by Bcl-2 [30,57]. The evidence of Bcl-2 family
involvement in seizure-induced neuronal cell death has
been demonstrated in recent studies, and both pro-
apoptotic and anti-apoptotic Bcl-2 family proteins were
found to be activated by seizures [1,58]. However, con-
flicting results on the expressional regulation of Bcl-2
family proteins in seizure-induced neuronal cell death
have emerged [1,58]. The reason for the discrepancy is
currently not well elucidated, but may be related to the
severity and duration of the disease conditions, or differ-
ences in the experimental methods employed. Increased
Bax translocation from cytosol to mitochondria in the
hippocampus has been reported in an animal model of
KA-induced epileptic seizures [59]. Bax has been
detected in clusters and accumulations on the outer sur-
face of mitochondria in the hippocampal neurons after
intra-amygdala KA-induced seizures [60]. In the present
study, we observed that the progressive translocation of
cytosolic Bax to the mitochondria, alongside an increase in
cytosolic presence of cytochrome c, are indicative of an
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interplay between Bax and cytochrome c-dependent apop-
totic cell death in the hippocampus following status epilep-
ticus. Whereas Bcl-2 is reported to be upregulated during
seizure-induced neuronal cell death [58], the expression of
Bcl-2 did not show significant changes in our present
study. This discrepancy may be related to the highly spe-
cific functions and subcellular locations of Bax and Bcl-2;
Bax protein is found in both cytoplasmic and mitochon-
drial compartments, and Bcl-2 protein is largely mitochon-
drial [1,55,56]. The present study also provided novel
results to suggest that upregulation of UCP2 in the hippo-
campus following experimental status epilepticus exerts its
anti-apoptotic action by interacting with Bax mitochondrial
translocation and downstream cytochrome c-dependent
apoptotic cascades. Overexpression of UCP2 in transgenic
mice ameliorated ischemia-induced Bcl-2 suppression in
the brain [47]. In skin cancer cells, upregulation of UCP2
blocked p53 mitochondrial translocation, which regulates
the pro-apoptotic effector Bax and reduced apoptosis dur-
ing early tumor promotion [61]. Therefore, we suggest that
the upregulated UCP2 in the hippocampus may prevent
the mitochondrial translocation of Bax by stabilizing the
inner mitochondrial membrane potential, resulting in an
antagonism against the downstream apoptotic events under
prolonged epileptic challenges.
Considerable controversy exists among reported models
of seizure-induced damage with regards to the distribution,
magnitude or form of neuronal cell death [1,2,22,62]. The
nature of hippocampal neuronal cell death following pro-
longed seizure was reported to be either apoptotic, necrotic
or both [1,22,62,63]. Programmed cell death mechanisms
associated with cellular apoptosis have been shown to be
activated after experimental status epilepticus [1,63].
Whereas CA3 neurons in the ipsilateral hippocampus
exhibited a mild degree of necrosis or the intermediate
forms of neuronal damage [22] that may be directly related
to KA excitatotoxicity, our experimental model revealed
that seizure-induced apoptotic cell death via cytochrome c/
caspase-3-dependent signaling cascade was detected in the
vulnerable CA3 neurons after a low dose of intrahippo-
campal administration of KA. We found that the degree of
dysfunction of complex I respiratory chain enzyme was
similar at 3 h and 24 h after experimental status epilepti-
cus. This implied that the complex I dysfunction did not
progress beyond 24 h in this animal model. In addition,
our previous study found that preserved mitochondrial
ultrastructural integrity and maintained energy metabolism
3 to 7 days following experimental status epilepticus is
associated specifically with apoptotic, not necrotic, cell
death in hippocampal CA3 neurons [22]. It follows that
differences in animal models of seizures, variations in dur-
ation and intensity of the induced seizure activity, and
metabolic disturbances after seizures are all contributing
factors that determine the level of energy production in the
mitochondria, leading eventually to diverse neuronal cell
death fate in vulnerable regions of the hippocampus.
Our results showed a temporal decrease in PPARγ ex-
pression 6 h after experimental status epilepticus, followed
by a significant increase of expression from 12 to 48 h in
the hippocampal CA3 subfield. Whereas the design of the
present study did not allow us to address the underlying
mechanism, we are aware that a transient decrease in the
expression of PPARγ protein under pathological conditions
such as hypoxia, cerebral ischemia and interferon-γ or
nerve growth factor treatment have been reported in neur-
onal and non-neuronal cells [38,64-66]. This effect may be
attributed to the activation of ubiquitin-proteasome path-
way or cytokines and inflammatory responses [38,64,67].
At the same time, transcription factors such as NF-κB, AP-
1 and STATs are known to regulate cytokine gene expres-
sion and inflammatory response [68]. We have demon-
strated previously [19] that significantly augmented
nucleus-bound translocation of NF-κB and DNA binding
activity of NF-κB in hippocampal CA3 neurons and glial
cells occurs as early as 30 minutes after the elicitation of
sustained seizure activity. Therefore, the transient decrease
of PPARγ expression in the hippocampus during experi-
mental status epilepticus may be related to activation of
NF-κB and other inflammatory responses. However, the
interrelationship between NF-κB and PPARγ in this experi-
mental paradigm warrants further exploration.
Conclusions
We demonstrated that activation of PPARγ upregulated
mitochondrial UCP2 expression, which decreased overpro-
duction of ROS, improved mitochondrial complex I dys-
function, inhibited mitochondrial translocation of Bax and
prevented cytosolic release of cytochrome c by stabilizing
the mitochondrial transmembrane potential, leading to
amelioration of apoptotic neuronal cell death in the hippo-
campus following status epilepticus. These findings may
offer a new vista in the development of more effective strat-
egies to enhance this endogenous protective mechanism
and reduce brain damage caused by status epilepticus.
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